- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04604691
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
February 20, 2022 updated by: Seoul National University Hospital
Blinatumomab for Minimal Residual Disease Before Hematopoietic Stem Cell Transplantation With Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease. 1 Cycle of blinatumomab treatment followed by hematopoietic stem cell transplantation.
Blinatumomab has approved to treat adults and children with B-cell precursor ALL who are in remission but still have MRD.
However, data on the effects and safety of blinatumomab in children with B-precursor ALL with MRD positive are insufficient.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Immunophenotypic evidence of Cluster of Differentiation 19 (CD19) positive B precursor ALL
- Age <18 years at the time of informed consent/assent
- B cell precursor ALL in first or later hematologic complete remission (CR) defined as less than 5% blasts in bone marrow after at least three intense chemotherapy blocks
- Persistent or recurrent MRD ≥10^-4 in an assay with a minimum sensitivity of 10^-5 before hematopoietic stem cell transplantation
- Bone marrow function as defined below: Absolute neutrophil count ≥1,000/μL, Platelets ≥50,000/μL (transfusion permitted), Hemoglobin level ≥9 g/dL (transfusion permitted)
- Renal and hepatic function as defined below: Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline phosphatase (AP) < 2 x upper limit of normal (ULN), Total bilirubin <1.5 x ULN, Creatinine clearance ≥ 50 mL/min
- Negative HIV test, negative hepatitis B (HBsAg) and hepatitis C virus (anti-HCV) test
- Negative pregnancy test in women of childbearing potential
Exclusion Criteria:
- Presence of circulating blasts or current extramedullary involvement by ALL
- History of relevant central nervous system (CNS) pathology or current relevant CNS pathology (e.g. seizure, epilepsy, paresis, aphasia, stroke, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis) with the except of CNS leukemia that is well controlled with intrathecal therapy
- Current infiltration of cerebrospinal fluid by ALL
- History of or active relevant autoimmune disease
- Systemic cancer chemotherapy within 2 weeks prior to study treatment (except for intrathecal prophylaxis)
- Radiotherapy within 4 weeks prior to study treatment
- Autologous hematopoietic stem cell transplantation (HSCT) within six weeks prior to study treatment
- Therapy with monoclonal antibodies (rituximab, alemtuzumab) within 4 weeks prior to study treatment
- Treatment with any investigational product within 4 weeks prior to study treatment
- Known hypersensitivity to immunoglobulin or to any other component of the study drug formulation
- Active malignancy other than ALL with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
- Active infection, any other concurrent disease or medical condition that are deemed to interfere with the conduct of the study as judged by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Blinatumomab Treatment
|
Blinatumomab will be administered as a continuous intravenous (CIV) infusion at a constant flow rate over four weeks followed by a two-week infusion free interval.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety evaluation including cytokine release syndrome
Time Frame: At the latest possible timepoint prior to the initiation of transplant conditioning or after 30 days of Blinatumomab treatment
|
The incidence of treatment-emergent and treatment-related adverse events
|
At the latest possible timepoint prior to the initiation of transplant conditioning or after 30 days of Blinatumomab treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete MRD response status after 1 cycle of blinatumomab
Time Frame: 28 Days
|
28 Days
|
Hematologic Relapse-Free Survival (RFS)
Time Frame: 24 Months
|
24 Months
|
Overall Survival (OS)
Time Frame: 24 Months
|
24 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2022
Primary Completion (Anticipated)
March 1, 2023
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
October 21, 2020
First Submitted That Met QC Criteria
October 21, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Actual)
March 8, 2022
Last Update Submitted That Met QC Criteria
February 20, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplastic Processes
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Neoplasm, Residual
- Antineoplastic Agents
- Blinatumomab
Other Study ID Numbers
- 20197007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Minimal Residual Disease
-
Nanfang Hospital of Southern Medical UniversityUnknownMinimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell TransplantationChina
-
University of LeicesterActive, not recruitingCancerUnited Kingdom
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)WithdrawnAcute Myeloid Leukemia | Minimal Residual Disease NegativityUnited States
-
Karolinska University HospitalMedical University of Graz; Aarhus University Hospital; Centre Hospitalier Universitaire... and other collaboratorsEnrolling by invitationPancreatic AdenocarcinomaSweden
-
University Hospital, Clermont-FerrandUnknownMinimal Residual Disease | Fertility PreservationFrance
-
AmgenTerminatedMyelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AMLUnited States, Canada, Germany, Netherlands
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
University Hospital, Clermont-FerrandUnknownMinimal Residual Disease | Fertility PreservationFrance
-
Guangdong Provincial People's HospitalShenzhen Chipscreen Biosciences Co.LtdRecruitingMinimal Residual Disease | AML, AdultChina
-
Xianmin Song, MDRecruiting
Clinical Trials on Blinatumomab for Injection
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingAcute Lymphoblastic Leukemia, Adult B-CellFrance
-
National Research Center for Hematology, RussiaRecruitingPrecursor Cell Lymphoblastic Leukemia-LymphomaRussian Federation
-
Bio-Thera SolutionsNot yet recruiting
-
AmgenCompletedNon-Hodgkin's LymphomaUnited States, Australia, Italy, United Kingdom, Germany, France
-
PETHEMA FoundationTerminatedPhiladelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALLSpain
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
University of Maryland, BaltimoreActive, not recruitingMixed Phenotype Acute Leukemia (MPAL) | Measurable Residual Disease (MRD)United States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingAcute Lymphoid Leukemia | Philadelphia Chromosome-Negative B-Cell PrecursorItaly
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States